Polaris Capital Management LLC Buys Shares of 24,500 Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Polaris Capital Management LLC acquired a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 24,500 shares of the company's stock, valued at approximately $910,000. Polaris Capital Management LLC owned 0.05% of Amphastar Pharmaceuticals at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. GAMMA Investing LLC grew its stake in shares of Amphastar Pharmaceuticals by 70.0% in the third quarter. GAMMA Investing LLC now owns 663 shares of the company's stock worth $32,000 after purchasing an additional 273 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. grew its stake in shares of Amphastar Pharmaceuticals by 53.4% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company's stock worth $56,000 after purchasing an additional 398 shares during the last quarter. Asset Management One Co. Ltd. bought a new stake in shares of Amphastar Pharmaceuticals in the third quarter worth about $78,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Amphastar Pharmaceuticals by 20.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company's stock worth $85,000 after purchasing an additional 301 shares during the last quarter. Finally, KBC Group NV boosted its position in Amphastar Pharmaceuticals by 43.1% during the 4th quarter. KBC Group NV now owns 2,159 shares of the company's stock valued at $80,000 after acquiring an additional 650 shares in the last quarter. 65.09% of the stock is owned by institutional investors.

Insider Transactions at Amphastar Pharmaceuticals

In other news, Director Richard K. Prins sold 10,000 shares of the business's stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $43.77, for a total value of $437,700.00. Following the sale, the director now directly owns 30,471 shares of the company's stock, valued at $1,333,715.67. The trade was a 24.71 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Rong Zhou sold 7,000 shares of the business's stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $44.42, for a total value of $310,940.00. Following the completion of the sale, the executive vice president now directly owns 118,469 shares in the company, valued at approximately $5,262,392.98. This represents a 5.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 27.10% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. StockNews.com cut Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, November 1st. Wells Fargo & Company assumed coverage on Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They set an "equal weight" rating and a $55.00 price objective on the stock. Finally, Piper Sandler cut Amphastar Pharmaceuticals from an "overweight" rating to a "neutral" rating and cut their price objective for the company from $66.00 to $36.00 in a research report on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $50.33.

Amphastar Pharmaceuticals Stock Down 1.8 %

Shares of AMPH traded down $0.59 during mid-day trading on Friday, reaching $31.16. The company had a trading volume of 273,983 shares, compared to its average volume of 507,472. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The firm has a 50-day moving average price of $37.36 and a 200 day moving average price of $43.49. Amphastar Pharmaceuticals, Inc. has a 52 week low of $31.09 and a 52 week high of $56.38. The company has a market capitalization of $1.50 billion, a price-to-earnings ratio of 10.39, a price-to-earnings-growth ratio of 2.07 and a beta of 0.81.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.